Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Released Mar 25, 2024, after the close
10-K filed Mar 26, 2024, 86 days after period end · 0001410578-24-000297
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.06M | $759.14K | — | — |
| Net Income | -$2.80M |
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
| -$3.86M |
| -$9.76M |
| -$8.51M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
